Amphastar Pharmaceuticals, Inc.
Amphastar Pharmaceuticals develops, manufactures, and sells generic and proprietary injectable products. Products include BAQSIMI for severe hypoglycemia, Primatene Mist for mild asthma symptoms, Enoxaparin for deep vein thrombosis prevention, and REXTOVY and Naloxone for opioid overdose treatment. The company also offers a range of other injectable products, including anesthetics, analgesics, and diagnostic agents. Additionally, Amphastar develops generic product candidates and distributes recombinant human insulin APIs and porcine insulin API.
Overview
Strengths
- Our discounted cash flow model points to 45% upside (target price 41.38 USD), and even our pessimistic growth scenario implies 26%: a margin of safety.
- Valued below its Drug Manufacturers - Specialty & Generic peers: P/E 13.3x vs. a median of 20.6x, P/FCF 10.9x vs. a median of 21.4x and EV/EBITDA 8.2x vs. a median of 12.9x.
- Consistent growth: revenue has compounded at 14.3% a year over 6 years, rising in 5 of them.
- Shareholder-friendly capital allocation: the share count has shrunk by 1.7% a year over the last three years through buybacks.
- Skin in the game: insiders own 31% of the shares, aligning management with shareholders.
- Cheaper than its own history: EV/EBITDA 8.2x vs. a historical average of 25.0x.
Weaknesses
- Unstable profitability: operating margin ranged from 0% to 31% over the last 7 years, with operating losses in 1 of them.
Key Financial Data